Nilotinib in Parkinson's Disease

NCT03205488 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
DRUG: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
DRUG: Placebo

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]